These system-shifting therapies come along every few years, but this is different

An independent review has found that New Zealand's Pharmac needs to make significant organisational changes over the next five years to meet public and stakeholder expectations.

According to the survey, 97 per cent of GPs agreed they were concerned about the influence of medical misinformation, having seen a shift in attitudes and behaviour amongst their patient community.

A world-first clinical trial launched in Melbourne is being hailed as a potential ‘game-changer’ for the way people with bowel cancer are treated.

According to Bupa's annual Pulse Check, based on a survey of 2,000 people, almost one in five, equating to around four million people, said they would consider prescription medicines for weight loss.

Medicines Australia has announced the appointment of Rachael Coghlan as its communications director and a new executive team member.

Sharon Winton, the CEO and director of Lymphoma Australia, said, “Patients living with DLBCL deserve options at every stage of their treatment journey. The availability of another treatment option for patients who have already undergone two or more lines of therapy acknowledges this need and is welcomed by the community.”

At its March meeting, surrounded by controversy following the decision to defer multiple submissions, the Pharmaceutical Benefits Advisory Committee delivered recommendations for high-profile cancer therapies, including one funded outside the PBS before it was approved, and several treatments for a chronic autoimmune disease.

Joana De Castro, the managing director of Johnson & Johnson Innovative Medicine, said the PBS listing is “long overdue.”

Research led by Monash University has found that a commonly used diabetes medicine can reduce the pain of people with knee osteoarthritis and overweight or obesity, possibly delaying the need for knee replacements.

The health election debate mainly concerned bulk billing. New bureaucracies are rarely the solution to anything, and the challenge of faster funded access to new health technologies, particularly when advisory committees with power appear opposed. The complexity of weight-loss therapies presents opportunities.

“For adults over 50 who live with the challenges of chronic health diseases, like COPD and asthma, RSV can be extremely serious,” said Mark Brooke, the CEO of Lung Foundation Australia.

This publication has and will continue to argue that processes like the HTA review simply cannot deliver the reform people expect because it's not an enabling policy framework. It will deliver targeted adjustments to the access barrier. Is that what stakeholders want?

The release of the Trump administration's terms of reference for its trade negotiations with India has revealed no significant interest in pharmaceutical issues, despite the country's standing as one of the worst offenders on intellectual property protection.

Roche has announced it will invest US$50 billion in the US over the next few years in a move that appears aimed at mitigating the risk of tariffs.

Pfizer has launched Part of the Story to mark World Book Day today, advocating a global campaign to help reimagine traditional cancer narratives and keep pace with science.

The US biopharmaceutical industry will welcome the Trump administration's move to scrap the so-called 'pill penalty' introduced as part of the Biden administration's Inflation Reduction Act but will be less supportive of other proposed measures.

Researchers at the University of Queensland are attempting to create a vaccine in just 150 days to demonstrate their ability to respond to a pandemic as part of a program backed by the Coalition for Epidemic Preparedness Innovations.

New research from the Sydney-based Centenary Institute has found that switching off a specific protein in liver cells could help prevent the early development of liver cancer.

Investors have shrugged off concerns over US President Donald Trump's planned tariffs on pharmaceutical imports with CSL's share price closing up over 2 per cent yesterday.